

Daniel D De Carvalho

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6497754/daniel-d-de-carvalho-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

71
papers

5,304
citations

32
h-index

72
g-index

102
ext. papers

7,171
ext. citations

17.7
avg, IF

5.85
L-index

#	Paper	IF	Citations
71	Epigenetic activation of plasmacytoid DC drives IFNAR-dependent therapeutic differentiation of AML.. <i>Cancer Discovery</i> , 2022 ,	24.4	1
70	Identification of the global miR-130a targetome reveals a role for TBL1XR1 in hematopoietic stem cell self-renewal and t(8;21) AML.. <i>Cell Reports</i> , 2022 , 38, 110481	10.6	0
69	PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.. <i>Nature Chemical Biology</i> , 2022 ,	11.7	3
68	H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2114324119	11.5	2
67	Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis. <i>Cancer Discovery</i> , 2021 , 11, 2707-2725	24.4	4
66	The next generation of DNMT inhibitors.. <i>Nature Cancer</i> , 2021 , 2, 1000-1001	15.4	2
65	DNA hypomethylating agents increase activation and cytolytic activity of CD8 T cells. <i>Molecular Cell</i> , 2021 , 81, 1469-1483.e8	17.6	19
64	Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4230-4244	12.9	9
63	Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential. <i>STAR Protocols</i> , 2021 , 2, 100549	1.4	
62	Mapping the cellular origin and early evolution of leukemia in Down syndrome. <i>Science</i> , 2021 , 373,	33.3	8
61	The Transition from Quiescent to Activated States in Human Hematopoietic Stem Cells Is Governed by Dynamic 3D Genome Reorganization. <i>Cell Stem Cell</i> , 2021 , 28, 488-501.e10	18	11
60	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , 2021 , 23, 87-98	23.4	53
59	Clinical advances in targeting epigenetics for cancer therapy. <i>FEBS Journal</i> , 2021 ,	5.7	12
58	Spliceosome-Targeted Therapies Induce dsRNA Responses. <i>Immunity</i> , 2021 , 54, 11-13	32.3	2
57	DNA Methylation based prognostic subtypes of chordoma tumors in tissue and plasma. <i>Neuro-Oncology</i> , 2021 ,	1	2
56	Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. <i>Nature Medicine</i> , 2020 , 26, 1044-1047	50.5	76
55	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020 , 26, 1041-1043	50.5	72

54	Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 1312-1329	24.4	34
53	Using epigenetic data to estimate immune composition in admixed samples. <i>Methods in Enzymology</i> , 2020 , 636, 77-92	1.7	
52	Mitochondrial carrier homolog 2 is necessary for AML survival. <i>Blood</i> , 2020 , 136, 81-92	2.2	8
51	Reactivation of Endogenous Retroelements in Cancer Development and Therapy. <i>Annual Review of Cancer Biology</i> , 2020 , 4, 159-176	13.3	15
50	Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency. <i>Nature</i> , 2020 , 588, 169-173	50.4	48
49	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. <i>European Journal of Cancer</i> , 2020 , 139, 135-148	7.5	12
48	Nucleolar RNA polymerase II drives ribosome biogenesis. <i>Nature</i> , 2020 , 585, 298-302	50.4	50
47	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors 2020 , 8,		12
46	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , 2020 , 12, 1317-1332	4.4	6
45	The role of DNA-demethylating agents in cancer therapy. <i>Pharmacology & Therapeutics</i> , 2020 , 205, 107416.9	16.9	6
44	Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. <i>Nature Protocols</i> , 2019 , 14, 2749-2780	18.8	47
43	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019 , 19, 151-161	31.3	216
42	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop 2019 , 7, 131		41
41	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas. <i>Cancer Cell</i> , 2019 , 35, 782-797.e8	24.3	52
40	The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids. <i>Cell Stem Cell</i> , 2019 , 24, 621-636.e16	18	19
39	Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells. <i>Nature Communications</i> , 2019 , 10, 1436	17.4	21
38	The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy. <i>Trends in Cell Biology</i> , 2019 , 29, 31-43	18.3	54
37	DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 5729-5731	12.9	5

36	Methods to detect endogenous dsRNA induction and recognition. <i>Methods in Enzymology</i> , 2019 , 629, 35-51	1.7	1
35	GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. <i>Science Immunology</i> , 2019 , 4,	2.8	34
34	A chemical biology toolbox to study protein methyltransferases and epigenetic signaling. <i>Nature Communications</i> , 2019 , 10, 19	17.4	69
33	LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. <i>Cell</i> , 2018 , 174, 549-563. e19	26.4	264
32	Mammary molecular portraits reveal lineage-specific features and progenitor cell vulnerabilities. <i>Journal of Cell Biology</i> , 2018 , 217, 2951-2974	7.3	20
31	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , 2018 , 563, 579-583	50.4	344
30	TGF- β -associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. <i>Nature Communications</i> , 2018 , 9, 4692	17.4	198
29	Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. <i>Nature Immunology</i> , 2018 , 19, 571-582	19.1	80
28	Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer. <i>Trends in Cancer</i> , 2018 , 4, 583-597	12.5	40
27	Epigenetic regulation of nitric oxide synthase 2, inducible (Nos2) by NLRC4 inflammasomes involves PARP1 cleavage. <i>Scientific Reports</i> , 2017 , 7, 41686	4.9	20
26	Early-life antibiotic treatment enhances the pathogenicity of CD4 T cells during intestinal inflammation. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 893-900	6.5	19
25	O-Acetylation of Peptidoglycan Limits Helper T Cell Priming and Permits Staphylococcus aureus Reinfection. <i>Cell Host and Microbe</i> , 2017 , 22, 543-551.e4	23.4	24
24	BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. <i>Cell Death and Disease</i> , 2017 , 8, e31114	9.8	6
23	Cell-free DNA as a post-treatment surveillance strategy: current status. <i>Seminars in Oncology</i> , 2017 , 44, 330-346	5.5	19
22	Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. <i>Cancer Cell</i> , 2016 , 30, 337-348	24.3	121
21	Pharmacological DNA demethylation: Implications for cancer immunotherapy. <i>Oncotarget</i> , 2016 , 5, e1090077	7.2	17
20	Pre-neoplastic epigenetic disruption of transcriptional enhancers in chronic inflammation. <i>Oncotarget</i> , 2016 , 7, 15772-86	3.3	19
19	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016 , 30, 891-908	24.3	135

18	IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment. <i>Cancer Research</i> , 2015 , 75, 3788-99	10.1	106
17	Symmetrical Dose-Dependent DNA-Methylation Profiles in Children with Deletion or Duplication of 7q11.23. <i>American Journal of Human Genetics</i> , 2015 , 97, 216-27	11	46
16	DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. <i>Cell</i> , 2015 , 162, 961-73	56.2	705
15	Aberrant DNA methylation reprogramming during induced pluripotent stem cell generation is dependent on the choice of reprogramming factors. <i>Cell Regeneration</i> , 2014 , 3, 4	2.5	19
14	High-throughput DNA analysis shows the importance of methylation in the control of immune inflammatory gene transcription in chronic periodontitis. <i>Clinical Epigenetics</i> , 2014 , 6, 15	7.7	17
13	Gene body methylation can alter gene expression and is a therapeutic target in cancer. <i>Cancer Cell</i> , 2014 , 26, 577-90	24.3	662
12	Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in non-small cell lung cancer cells. <i>PLoS ONE</i> , 2014 , 9, e99484	3.7	11
11	SNF5 is an essential executor of epigenetic regulation during differentiation. <i>PLoS Genetics</i> , 2013 , 9, e1003459	6	38
10	DNA methylation screening identifies driver epigenetic events of cancer cell survival. <i>Cancer Cell</i> , 2012 , 21, 655-667	24.3	198
9	Polycomb-repressed genes have permissive enhancers that initiate reprogramming. <i>Cell</i> , 2011 , 147, 1283-94	30.4	146
8	BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. <i>Oncogene</i> , 2011 , 30, 223-33	9.2	40
7	OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 14497-502	11.5	104
6	Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. <i>PLoS Genetics</i> , 2011 , 7, e1001286	6	88
5	Epigenetic modifications as therapeutic targets. <i>Nature Biotechnology</i> , 2010 , 28, 1069-78	44.5	580
4	The cell wall fraction from <i>Fonsecaea pedrosoi</i> stimulates production of different profiles of cytokines and nitric oxide by murine peritoneal cells in vitro. <i>Mycopathologia</i> , 2010 , 170, 89-98	2.9	4
3	DNA methylation and cellular reprogramming. <i>Trends in Cell Biology</i> , 2010 , 20, 609-17	18.3	164
2	DNA-Demethylating Agents enhance cytolytic activity of CD8+ T Cells and anti-tumor immunity		1
1	Sensitive and reproducible cell-free methylome quantification with synthetic spike-in controls		1

